Stay updated on market trends for PRAX. Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate Praxis Precision Medicines' ulixacaltamide study for ...
Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback